Emtora Biosciences is a clinical-stage biopharmaceutical company based in San Antonio, Texas, developing eRapa, an encapsulated form of the approved drug rapamycin. The company is advancing eRapa for treatment of Familial Adenomatous Polyposis (FAP) and other cancer indications. Emtora plans to use a newly awarded CPRIT grant to complete a randomized, placebo-controlled Phase 3 trial of eRapa in FAP and to continue development work. It is also conducting a fully enrolled multicenter Phase 2 trial in FAP with primary endpoint data expected in January 2023, and a grant-funded Phase 2 trial in Non-Muscle Invasive Bladder Cancer with data expected in 2024. Financially, Emtora received a $16.9M non-dilutive grant from the Cancer Prevention & Research Institute of Texas (CPRIT) and had previously received a $3M CPRIT Seed Award in 2019. The CPRIT award requires certification of 50% matching funds; the company is exploring fundraising and partnering options to secure the required matching funds for Year 1. Emtora Biosciences is a clinical-stage biopharmaceutical company headquartered in San Antonio, Texas, that holds the exclusive license to eRapa, a targeted formulation of rapamycin originally developed at UT Health San Antonio. eRapa is being investigated to prevent cancer and other age-related medical conditions and is being developed for indications with serious unmet medical needs. In preclinical mouse models the company has demonstrated that eRapa can prevent formation of polyps associated with Familial Adenomatous Polyposis (FAP). Emtora has filed an IND, obtained approval to pursue a 505(b)(2) abbreviated regulatory pathway, received Orphan Drug designation, and is gaining safety and dose information in an ongoing Phase Ib clinical study. The company recently received a $3.0 million SEED Award grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support clinical development. The CPRIT award will fund a Phase 2a oral study in 30 FAP patients to measure changes in polyp number and size over a 12-month treatment course.

Total raised

$20M

Funding rounds

2

Latest round

Grant

Latest activity

Aug 2022